News

In the wake of this sell-off, a critical question arises about whether LLY stock represents a buying opportunity.
Ladies and gentlemen, thank you for standing by, and welcome to the Lilly Q2 2025 Earnings Conference Call. [Operator ...
Drugmaker Eli Lilly says their oral, daily GLP-1 pill, orforglipron, may offer similar weight loss results as weekly GLP-1 shots.
The main indexes finished well off their session highs after a disappointing batch of corporate earnings reports.
Eli Lilly raised its full-year profit forecast on Thursday, betting on surging demand for its blockbuster weight-loss drug, ...
Eli Lilly and Company (NYSE: LLY ) and Verve Therapeutics, Inc. (NASDAQ: VERV ) today announced that the tender offer to purchase all of the issued and outstanding shares ("Shares") of Verve's common ...
Investors and analysts say they expect Eli Lilly to report stronger quarterly sales and profit next week than Danish rival Novo Nordisk did on Tuesday, and are anxiously awaiting a full-year outlook ...
Eli Lilly and Company (NYSE: LLY) is included among the 14 Best Pharma Dividend Stocks to Buy in 2025. An array of pharmaceutical pills with the company’s logo on the bottle.
Drugmakers Sanofi, Eli Lilly, Novo Nordisk and AstraZeneca must face a lawsuit from two health centers accusing them of ...
On July 9, Eli Lilly and Company (NYSE:LLY) reported that the US Food and Drug Administration (FDA) approved a label update with a new recommended titration dosing schedule for Kisunla. Kisunla is ...
$2,700,000 of ELI LILLY AND COMPANY lobbying was just disclosed, from Q2 of 2025, in a new Lobbying Disclosure Act filing.
Eli Lilly outpaces Novo in the GLP-1 market with Tirzepatide and emerging blockbusters, signaling future growth. Read more on my Strong Buy rating for LLY.